Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients

Commentary: SARS-CoV-2 vaccines and cancer patients

(2021) C. Corti et al.   ANNALS OF ONCOLOGY

Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis

(2021) Adam Booth et al.   PLoS One

Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose

(2021) Evangelos Terpos et al.   BLOOD

Comparison of neutralizing antibody responses against SARS‐CoV ‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?

(2021) Evangelos Terpos et al.   AMERICAN JOURNAL OF HEMATOLOGY

Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell–Mediated Immune Suppression and Tumor Progression

(2020) Camila R. Consiglio et al.   Cancer Immunology Research

Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse

(2016) Yang Pu et al.   Science Translational Medicine